

## Supplementary Online Content

Ecker BL, Vollmer CM Jr, Behrman SW, et al. Role of adjuvant multimodality therapy after curative-intent resection of ampullary carcinoma. *JAMA Surg*.

Published online May 29, 2019. doi:10.1001/jamasurg.2019.1170

**eTable 1.** Univariate Analysis of Operative Characteristics and Postoperative Outcomes of Pancreatoduodenectomy, Stratified by Disease Pathology (n=5082)

**eTable 2.** Demographic and Clinicopathologic Variables of the Propensity Score-Matched Cohort, and Univariate Comparison Between Patients Receiving Surgery Alone or Adjuvant Therapy (n=162)

**eFigure 1.** Association of Adjuvant therapy and Overall Survival in the Unmatched Cohort, Stratified by Pathologic Stage (stage I: n=86; stage II: n=21; stage III: n=211)

**eFigure 2.** Association of Adjuvant Chemoradiotherapy Relative to Surgery Alone (left; n=79) or Chemotherapy Alone (right; n=75) on Recurrence-Free Survival in the Propensity Score-Matched Cohort

This supplementary material has been provided by the authors to give readers additional information about their work.


**eTable 1.** Univariate Analysis of Operative Characteristics and Postoperative Outcomes of Pancreatoduodenectomy, Stratified by Disease Pathology (n=5082)

Variable, N(%) or median (IQR) or mean (SD)	Ampullary adenocarcinoma (n=310)	All Other Pathologies (n=4,722)	P Value	
<i>Operative characteristics</i>				
Gland texture, soft	229 (73.9)	2,499 (52.9)	<.001	
Main pancreatic duct (mm)	3.8 (2.2)	3.9 (2.2)	.631	
Total FRS	4.3 (1.9)	3.6 (2.2)	<.001	
Prophylactic intraperitoneal drainage	271 (87.4)	4,085 (94.5)	<.001	
Prophylactic octreotide	160 (51.6)	1,204 (35.2)	<.001	
PG reconstruction	15 (4.8)	229 (4.8)	.821	
Biologic sealant	22 (7.1)	138 (3.1)	<.001	
<i>Postoperative outcomes</i>				
Complication	All (Accordion ≥1)	167 (57.8)	2,605 (55.2)	.385
	Major (Accordion ≥3)	57 (19.7)	891 (18.9)	.719
CR-POPF	83 (26.8)	557 (11.8)	<.001	
Percutaneous drainage	46 (15.6)	213 (10.7)	.012	
Therapeutic antibiotic(s)	118 (40.0)	786 (40.2)	.952	
Parenteral nutrition	78 (26.6)	555 (28.8)	.441	
Hospital LOS, days	9 [7-15]	8 [7-13]	.002	
Readmission, 90 days	44 (15.1)	335 (15.2)	.938	
Abbreviations: IQR interquartile range; SD standard deviation; FRS fistula risk score; PG pancreatogastrostomy; CR-POPF clinically relevant postoperative pancreatic fistula; LOS length of stay				

**eTable 2.** Demographic and Clinicopathologic Variables of the Propensity Score-Matched Cohort, and Univariate Comparison Between Patients Receiving Surgery Alone or Adjuvant Therapy (n=162)

		<b>Surgery Alone (%) n=81</b>	<b>Adjuvant Therapy (%) n=81</b>	<b>P Value</b>
Age (years)	<65	36 (44.4)	34 (42.0)	.717
	65-75	20 (24.7)	23 (28.4)	
	>75	25 (30.9)	23 (28.4)	
Race	White	66 (81.5)	75 (92.6)	.146
	Black	9 (11.1)	3 (3.7)	
	Asian/Other	2 (2.5)	2 (2.5)	
T classification	T1-2	33 (40.7)	33 (40.7)	.603
	T3-4	48 (59.3)	47 (58.0)	
N classification	Node-negative	28 (34.6)	30 (37.0)	.583
	Node-positive	52 (64.2)	51 (63.0)	
Perineural invasion	Absent	42 (51.9)	36 (44.4)	.637
	Present	38 (46.9)	44 (54.3)	

**eFigure 1.** Association of Adjuvant therapy and Overall Survival in the Unmatched Cohort, Stratified by Pathologic Stage (stage I: n=86; stage II: n=21; stage III: n=211)



**eFigure 2.** Association of Adjuvant Chemoradiotherapy Relative to Surgery Alone (left; n=79) or Chemotherapy Alone (right; n=75) on Recurrence-Free Survival in the Propensity Score-Matched Cohort

